Art. 19 Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 Novembe…

Reduction of the fee for marketing authorisation

In force
1.

By way of derogation from Regulation (EC) No 297/95, the fee for marketing authorisation shall be reduced by 50 % if the applicant is a hospital or a small or medium-sized enterprise and can prove that there is a particular public health interest in the Community in the advanced therapy medicinal product concerned.

2.

Paragraph 1 shall also apply to fees charged by the Agency for post-authorisation activities in the first year following the granting of the marketing authorisation for the advanced therapy medicinal product.

3.

Paragraphs 1 and 2 shall apply during the transitional periods laid down in Article 29.